Downloadable Synaptic Protein Database
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Heterozygous ATP-Binding Cassette Transporter G5 Gene Deficiency and Risk of Coronary Artery Disease
bioRxiv preprint doi: https://doi.org/10.1101/780734; this version posted September 27, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Heterozygous ATP-binding Cassette Transporter G5 Gene Deficiency and Risk of Coronary Artery Disease Short title: Heterozygous ABCG5 deficiency and risk of CAD Akihiro Nomura*, MD PhD, Connor A. Emdin*, DPhil, Hong Hee Won, PhD, Gina M. Peloso, PhD, Pradeep Natarajan, MD, Diego Ardissino, MD, John Danesh, FRCP DPhil, Heribert Schunkert, MD, Adolfo Correa, MD PhD, Matthew J. Bown, MD FRCS, Nilesh J. Samani, MD FRCP, Jeanette Erdmann, PhD, Ruth McPherson, MD, Hugh Watkins, MD PhD, Danish Saleheen, MD, Roberto Elosua, MD PhD, Masa-aki Kawashiri, MD PhD, Hayato Tada, MD PhD, Namrata Gupta, PhD, Svati H. Shah, MD MHS, Daniel J. Rader, MD, Stacey Gabriel, PhD, Amit V. Khera*, MD, Sekar Kathiresan*, MD *: These authors contributed equally Address for correspondence: Sekar Kathiresan, MD Verve Therapeutics 26 Landsdowne Street, 1st Floor Cambridge, MA 02139 Email: [email protected] Phone: 617 603 0070 bioRxiv preprint doi: https://doi.org/10.1101/780734; this version posted September 27, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Background: Familial sitosterolemia is a rare, recessive Mendelian disorder characterized by hyperabsorption and decreased biliary excretion of dietary sterols. -
Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism -
The Expression of the Human Apolipoprotein Genes and Their Regulation by Ppars
CORE Metadata, citation and similar papers at core.ac.uk Provided by UEF Electronic Publications The expression of the human apolipoprotein genes and their regulation by PPARs Juuso Uski M.Sc. Thesis Biochemistry Department of Biosciences University of Kuopio June 2008 Abstract The expression of the human apolipoprotein genes and their regulation by PPARs. UNIVERSITY OF KUOPIO, the Faculty of Natural and Environmental Sciences, Curriculum of Biochemistry USKI Juuso Oskari Thesis for Master of Science degree Supervisors Prof. Carsten Carlberg, Ph.D. Merja Heinäniemi, Ph.D. June 2008 Keywords: nuclear receptors; peroxisome proliferator-activated receptor; PPAR response element; apolipoprotein; lipid metabolism; high density lipoprotein; low density lipoprotein. Lipids are any fat-soluble, naturally-occurring molecules and one of their main biological functions is energy storage. Lipoproteins carry hydrophobic lipids in the water and salt-based blood environment for processing and energy supply in liver and other organs. In this study, the genomic area around the apolipoprotein genes was scanned in silico for PPAR response elements (PPREs) using the in vitro data-based computer program. Several new putative REs were found in surroundings of multiple lipoprotein genes. The responsiveness of those apolipoprotein genes to the PPAR ligands GW501516, rosiglitazone and GW7647 in the HepG2, HEK293 and THP-1 cell lines were tested with real-time PCR. The APOA1, APOA2, APOB, APOD, APOE, APOF, APOL1, APOL3, APOL5 and APOL6 genes were found to be regulated by PPARs in direct or secondary manners. Those results provide new insights in the understanding of lipid metabolism and so many lifestyle diseases like atherosclerosis, type 2 diabetes, heart disease and stroke. -
The Effect of Statin Treatment on Intratumoral Cholesterol Levels and LDL Receptor Expression: a Window-Of-Opportunity Breast Ca
Feldt et al. Cancer & Metabolism (2020) 8:25 https://doi.org/10.1186/s40170-020-00231-8 RESEARCH Open Access The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of- opportunity breast cancer trial Maria Feldt1,2* , Julien Menard1, Ann H. Rosendahl1,2, Barbara Lettiero1, Pär-Ola Bendahl1, Mattias Belting1,2,3 and Signe Borgquist1,4 Abstract Background: Deregulated lipid metabolism is common in cancer cells and the mevalonate pathway, which synthesizes cholesterol, is central in lipid metabolism. This study aimed to assess statin-induced changes of the intratumoral levels of cholesterol and the expression of the low-density lipoprotein receptor (LDLR) to enhance our understanding of the role of the mevalonate pathway in cancer cholesterol metabolism. Methods: This study is based on a phase II clinical trial designed as a window-of-opportunity trial including 50 breast cancer patients treated with 80 mg of atorvastatin/day for 2 weeks, between the time of diagnosis and breast surgery. Lipids were extracted from frozen tumor tissue sampled pre- and post-atorvastatin treatment. Intratumoral cholesterol levels were measured using a fluorometric quantitation assay. LDLR expression was evaluated by immunohistochemistry on formalin-fixed paraffin-embedded tumor tissue. Paired blood samples pre- and post- atorvastatin were analyzed for circulating low-density lipoprotein (LDL), high-density lipoprotein (HDL), apolipoprotein A1, and apolipoprotein B. In vitro experiments on MCF-7 breast cancer cells treated with atorvastatin were performed for comparison on the cellular level. Results: In the trial, 42 patients completed all study parts. From the paired tumor tissue samples, assessment of the cholesterol levels was achievable for 14 tumors, and for the LDLR expression in 24 tumors. -
Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease
International Journal of Molecular Sciences Review Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease Stanislav Kotlyarov Department of Nursing, Ryazan State Medical University, 390026 Ryazan, Russia; [email protected] Abstract: Chronic obstructive pulmonary disease (COPD) is the important medical and social problem. According to modern concepts, COPD is a chronic inflammatory disease, macrophages play a key role in its pathogenesis. Macrophages are heterogeneous in their functions, which is largely determined by their immunometabolic profile, as well as the features of lipid homeostasis, in which the ATP binding cassette transporter A1 (ABCA1) plays an essential role. The objective of this work is the analysis of the ABCA1 protein participation and the function of reverse cholesterol transport in the pathogenesis of COPD. The expression of the ABCA1 gene in lung tissues takes the second place after the liver, which indicates the important role of the carrier in lung function. The participation of the transporter in the development of COPD consists in provision of lipid metabolism, regulation of inflammation, phagocytosis, and apoptosis. Violation of the processes in which ABCA1 is involved may be a part of the pathophysiological mechanisms, leading to the formation of a heterogeneous clinical course of the disease. Keywords: chronic obstructive pulmonary disease; COPD; inflammation; ABCA1; reverse cholesterol transport; innate immune system Citation: Kotlyarov, S. Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive 1. Introduction Pulmonary Disease. Int. J. Mol. Sci. Chronic obstructive pulmonary disease (COPD) is one of the most widespread dis- 2021, 22, 3334. https://doi.org/ eases, it has great medical significance due to the high frequency of temporary and per- 10.3390/ijms22073334 sistent disability and mortality. -
1 CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on A
Page 1 of 55 Diabetes CETP inhibition improves HDL function but leads to fatty liver and insulin resistance in CETP-expressing transgenic mice on a high-fat diet Lin Zhu1,2, Thao Luu2, Christopher H. Emfinger1,2, Bryan A Parks5, Jeanne Shi2,7, Elijah Trefts3, Fenghua Zeng4, Zsuzsanna Kuklenyik5, Raymond C. Harris4, David H. Wasserman3, Sergio Fazio6 and John M. Stafford1,2,3,* 1VA Tennessee Valley Healthcare System, 2Division of Diabetes, Endocrinology, & Metabolism, 3Department of Molecular Physiology and Biophysics, 4Devision of Nephrology and Hypertension, Vanderbilt University School of Medicine. 5Division of Laboratory Sciences, Centers for Disease Control and Prevention. 6The Center for Preventive Cardiology at the Knight Cardiovascular Institute, Oregon Health & Science University. 7Trinity College of Art and Science, Duke University. * Address correspondence and request for reprints to: John. M. Stafford, 7445D Medical Research Building IV, Nashville, TN 37232-0475, phone (615) 936-6113, fax (615) 936- 1667 Email: [email protected] Running Title: CETP inhibition and insulin resistance Word Count: 5439 Figures: 7 Tables: 1 1 Diabetes Publish Ahead of Print, published online September 13, 2018 Diabetes Page 2 of 55 Abstract In clinical trials inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels but doesn’t robustly improve cardiovascular outcomes. About 2/3 of trial participants were obese. Lower plasma CETP activity is associated with increased cardiovascular risk in human studies, and protective aspects of CETP have been observed in mice fed a high-fat diet (HFD) with regard to metabolic outcomes. To define if CETP inhibition has different effects depending on the presence of obesity, we performed short- term anacetrapib treatment in chow- and HFD-fed CETP-transgenic mice. -
An Abundant Dysfunctional Apolipoprotein A1 in Human Atheroma
Cleveland State University EngagedScholarship@CSU Mathematics Faculty Publications Mathematics Department 2-1-2014 An Abundant Dysfunctional Apolipoprotein A1 in Human Atheroma Ying Huang Cleveland Clinic Joseph A. DiDonato Cleveland State University, [email protected] Bruce S. Levison Cleveland Clinic Dave Schmitt Cleveland Clinic Lin Li Cleveland Clinic Follow this and additional works at: https://engagedscholarship.csuohio.edu/scimath_facpub Part of the Mathematics Commons See next page for additional authors How does access to this work benefit ou?y Let us know! Repository Citation Huang, Ying; DiDonato, Joseph A.; Levison, Bruce S.; Schmitt, Dave; Li, Lin; Wu, Yuping; Buffa, Jennifer; Kim, Timothy; Gerstenecker, Gary S.; Gu, Xiaodong; Kadiyala, Chandra S.; Wang, Zeneng; Culley, Miranda K.; Hazen, Jennie E.; DiDonato, Anthony J.; Fu, Xiaoming; Berisha, Stela Z.; Peng, Daoquan; Nguyen, Truc T.; Liang, Shaohong; Chuang, Chia-Chi; Cho, Leslie; PLow, Edward F.; Fox, Paul L.; Gogonea, Valentin; Tang, W.H. Wilson; Parks, John S.; Fisher, Edward A.; Smith, Jonathan D.; and Hazen, Stanley L., "An Abundant Dysfunctional Apolipoprotein A1 in Human Atheroma" (2014). Mathematics Faculty Publications. 161. https://engagedscholarship.csuohio.edu/scimath_facpub/161 This Article is brought to you for free and open access by the Mathematics Department at EngagedScholarship@CSU. It has been accepted for inclusion in Mathematics Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more information, please contact [email protected]. Authors Ying Huang, Joseph A. DiDonato, Bruce S. Levison, Dave Schmitt, Lin Li, Yuping Wu, Jennifer Buffa, Timothy Kim, Gary S. Gerstenecker, Xiaodong Gu, Chandra S. Kadiyala, Zeneng Wang, Miranda K. Culley, Jennie E. -
Apolipoprotein A4 Gene (APOA4) (Chromosome 11/Haplotypes/Intron Loss/Coronary Artery Disease/Apoal-APOC3 Deficiency) Sotirios K
Proc. Natl. Acad. Sci. USA Vol. 83, pp. 8457-8461, November 1986 Biochemistry Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4) (chromosome 11/haplotypes/intron loss/coronary artery disease/APOAl-APOC3 deficiency) SOTIRios K. KARATHANASIS*t, PETER OETTGEN*t, ISSAM A. HADDAD*t, AND STYLIANOS E. ANTONARAKISt *Laboratory of Molecular and Cellular Cardiology, Department of Cardiology, Children's Hospital and tDepartment of Pediatrics, Harvard Medical School, Boston, MA 02115; and tDepartment of Pediatrics, Genetics Unit, The Johns Hopkins University, School of Medicine, Baltimore, MD 21205 Communicated by Donald S. Fredrickson, July 11, 1986 ABSTRACT The genes coding for three proteins of the APOC3 deficiency and premature coronary artery disease plasma lipid transport system-apolipoproteins Al (APOAI), (13-15), hypertriglyceridemia (16), and hypoalphalipopro- C3 (APOC3), and A4 (APOA4)-are closely linked and teinemia (17). tandemly organized on the long arm ofhuman chromosome 11. In this report the nucleotide sequence of the human In this study the human APOA4 gene has been isolated and APOA4 gene has been determined. The results suggest that characterized. In contrast to APOAl and APOC3 genes, which the APOAI, APOC3, and APOA4 genes were derived from a contain three introns, the APOA4 gene contains only two. An common evolutionary ancestor and indicate that during intron interrupting the 5' noncoding region of the APOA1 and evolution the APOA4 gene lost one of its ancestral introns. APOC3 mRNAs is absent from the corresponding position of Screening of the APOA4 gene region for polymorphisms the APOA4 mRNA. However, similar to APOAI and APOC3 showed that two different Xba I restriction endonuclease genes, the introns of the APOA4 gene separate nucleotide sites are polymorphic in Mediterranean and Northern Euro- sequences coding for the signal peptide and the amphipathic pean populations. -
Increased Phospholipid Transfer Protein Activity Associated with the Impaired Cellular Cholesterol Efflux in Type 2 Diabetic Subjects with Coronary Artery Disease
Tohoku J. Exp. Med., 2007,Cholesterol 213, 129-137 Efflux and PLTP Activity in Diabetes with CAD 129 Increased Phospholipid Transfer Protein Activity Associated with the Impaired Cellular Cholesterol Efflux in Type 2 Diabetic Subjects with Coronary Artery Disease 1,2 2 2 2 3 NEBIL ATTIA, AMEL NAKBI, MAHA SMAOUI, RAJA CHAABA, PHILIPPE MOULIN, 4 4 5 SONIA HAMMAMI, KHALDOUN BEN HAMDA, FRANÇOISE CHANUSSOT and 2 MOHAMED HAMMAMI 1Biology Department, Faculty of Sciences, University November 7th at Carthage, Bizerte, Tunisia 2Biochemistry Laboratory, UR 08-39, Faculty of Medicine, University of Monastir, Monastir, Tunisia 3U11 Cardiovascular Unit, Louis Pradel Hospital and INSERM U585, Lyon, France 4Departments of Internal Medicine (SH) and Cardiology (KBH), Monastir Hospital, Monastir, Tunisia 5INSERM U476, Faculty of Medecine la Timone, University Aix-Marseille II, Marseille, France ATTIA, N., NAKBI, A., SMAOUI, M., CHAABA, R., MOULIN, P., HAMMAMI, S., HAMDA, K.B., CHANUSSOT, F. and HAMMAMI, M. Increased Phospholipid Transfer Protein Activity Associated with the Impaired Cellular Cholesterol Efflux in Type 2 Diabetic Subjects with Coronary Artery Disease. Tohoku J. Exp. Med., 2007, 213 (2), 129-137 ── Reverse cholesterol transport (RCT) is the pathway, by which the excess of cholesterol is removed from peripheral cells to the liver. An early step of RCT is the efflux of free cholesterol from cell membranes that is mediated by high-density lipoproteins (HDL). Phospholipid transfer protein (PLTP) transfers phospholipids between apolipoprotein-B-containing lipo- proteins (i.e., chylomicrons and very low-density lipoproteins) and HDL. PLTP contrib- utes to the HDL maturation and increases the ability of HDL to extract the cellular choles- terol. -
Common Genetic Variations Involved in the Inter-Individual Variability Of
nutrients Review Common Genetic Variations Involved in the Inter-Individual Variability of Circulating Cholesterol Concentrations in Response to Diets: A Narrative Review of Recent Evidence Mohammad M. H. Abdullah 1 , Itzel Vazquez-Vidal 2, David J. Baer 3, James D. House 4 , Peter J. H. Jones 5 and Charles Desmarchelier 6,* 1 Department of Food Science and Nutrition, Kuwait University, Kuwait City 10002, Kuwait; [email protected] 2 Richardson Centre for Functional Foods & Nutraceuticals, University of Manitoba, Winnipeg, MB R3T 6C5, Canada; [email protected] 3 United States Department of Agriculture, Agricultural Research Service, Beltsville, MD 20705, USA; [email protected] 4 Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada; [email protected] 5 Nutritional Fundamentals for Health, Vaudreuil-Dorion, QC J7V 5V5, Canada; [email protected] 6 Aix Marseille University, INRAE, INSERM, C2VN, 13005 Marseille, France * Correspondence: [email protected] Abstract: The number of nutrigenetic studies dedicated to the identification of single nucleotide Citation: Abdullah, M.M.H.; polymorphisms (SNPs) modulating blood lipid profiles in response to dietary interventions has Vazquez-Vidal, I.; Baer, D.J.; House, increased considerably over the last decade. However, the robustness of the evidence-based sci- J.D.; Jones, P.J.H.; Desmarchelier, C. ence supporting the area remains to be evaluated. The objective of this review was to present Common Genetic Variations Involved recent findings concerning the effects of interactions between SNPs in genes involved in cholesterol in the Inter-Individual Variability of metabolism and transport, and dietary intakes or interventions on circulating cholesterol concen- Circulating Cholesterol trations, which are causally involved in cardiovascular diseases and established biomarkers of Concentrations in Response to Diets: cardiovascular health. -
Apoa4 Antibody Cat
ApoA4 Antibody Cat. No.: 6269 Western blot analysis of ApoA4 in chicken small intestine tissue lysate with ApoA4 antibody at 1 μg/mL Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Chicken, Human ApoA4 antibody was raised against a 20 amino acid synthetic peptide near the carboxy terminus of chicken ApoA4. IMMUNOGEN: The immunogen is located within the last 50 amino acids of ApoA4. TESTED APPLICATIONS: ELISA, WB ApoA4 antibody can be used for detection of ApoA4 by Western blot at 1 μg/mL. APPLICATIONS: Antibody validated: Western Blot in chicken samples. All other applications and species not yet tested. POSITIVE CONTROL: 1) Chicken Small Intestine Lysate Properties PURIFICATION: ApoA4 Antibody is affinity chromatography purified via peptide column. CLONALITY: Polyclonal ISOTYPE: IgG September 24, 2021 1 https://www.prosci-inc.com/apoa4-antibody-6269.html CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: ApoA4 Antibody is supplied in PBS containing 0.02% sodium azide. CONCENTRATION: 1 mg/mL ApoA4 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one STORAGE CONDITIONS: year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: APOA4 ALTERNATE NAMES: ApoA4 Antibody: Apolipoprotein A-IV, Apolipoprotein A4, Apo-AIV ACCESSION NO.: NP_990269 PROTEIN GI NO.: 71773110 GENE ID: 337 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References ApoA4 Antibody: Apolipoprotein A4 (also known as ApoA-IV) is a plasma protein that is O- linked glycoprotein after proteolytic processing. -
JUN-Mediated Downregulation of EGFR Signaling Is Associated With
Published OnlineFirst May 31, 2017; DOI: 10.1158/1535-7163.MCT-16-0564 Cancer Biology and Signal Transduction Molecular Cancer Therapeutics JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR- mutant NSCLC Cell Lines Kian Kani1,2, Carolina Garri1, Katrin Tiemann1, Paymaneh D. Malihi1, Vasu Punj3, Anthony L. Nguyen1, Janet Lee1, Lindsey D. Hughes1, Ruth M. Alvarez1, Damien M. Wood1, Ah Young Joo1, Jonathan E. Katz1, David B. Agus1,2, and Parag Mallick1,4 Abstract Mutations or deletions in exons 18–21 in the EGFR)are HCC827 cells increased gefitinib IC50 from 49 nmol/L to 8 present in approximately 15% of tumors in patients with non– mmol/L (P < 0.001). Downregulation of JUN expression small cell lung cancer (NSCLC). They lead to activation of the through shRNA resensitized HCC827 cells to gefitinib (IC50 EGFR kinase domain and sensitivity to molecularly targeted from 49 nmol/L to 2 nmol/L; P < 0.01). Inhibitors targeting therapeutics aimed at this domain (gefitinib or erlotinib). JUNwere3-foldmoreeffectiveinthegefitinib-resistant cells These drugs have demonstrated objective clinical response in than in the parental cell line (P < 0.01). Analysis of gene many of these patients; however, invariably, all patients acquire expression in patient tumors with EGFR-activating mutations resistance. To examine the molecular origins of resistance, we and poor response to erlotinib revealed a similar pattern as the derivedasetofgefitinib-resistant cells by exposing lung ade- top 260 differentially expressed genes in the gefitinib-resistant nocarcinoma cell line, HCC827, with an activating mutation in cells (Spearman correlation coefficient of 0.78, P < 0.01).